Minoryx Therapeutics doses first patient with leriglitazone in registration-enabling cALD NEXUS trial

by Minoryx Therapeutics

Pediatric Investigational Plan (PIP) for leriglitazone in X-ALD approved by EMA, allowing to file Marketing Authorization Application (MAA) in Europe based on NEXUS

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Theriva™ Biologics to Present Preclini...

by Theriva™ Biologics

Theriva™ Biologics has announced the presentation of preclinical da...

Photos Stream